INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2020

Souvenaid dietary supplement probably results in little to no difference in cognitive function or dementia progression in Alzheimer's disease.

A systematic review evaluated three randomized, placebo-controlled trials examining the dietary supplement Souvenaid in 1,097 participants with Alzheimer's disease (AD). In prodromal AD, Souvenaid showed little to no difference compared to placebo in the incidence of dementia after 24 months (RR 1.09, 95% CI 0.82 to 1.43). Across prodromal, mild, and mild-to-moderate AD, it probably resulted in little to no difference in global or specific cognitive functions or activities of daily living. A slight improvement on the Clinical Dementia Rating Sum of Boxes was observed in prodromal AD after 24 months, but this was below estimates of meaningful change. Adverse effects were low across trials, and two of the three included studies were funded by the manufacturer.

Study type
Systematic review of randomized controlled trials
Who was studied
1,097 community-dwelling participants with Alzheimer's disease (prodromal, mild, or mild-to-moderate)
What was measured
Incidence of dementia, cognitive function, functional performance, combined cognitive-functional outcomes, and adverse events

THE PAPER

Souvenaid for Alzheimer's disease.

Burckhardt M, Watzke S, Wienke A, Langer G, Fink A. Cochrane Database Syst Rev, 2020.

PubMed 33320335 ↗DOI 10.1002/14651858.cd011679 ↗

Nutrients & adequacyBrain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.